Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Sales 2022 | 17.99M 19.8M 27.18M | Sales 2023 | 33.56M 36.95M 50.72M | Capitalization | 128M 141M 194M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.41M -21.16M | Net income 2023 | -13M -14.31M -19.65M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.31M 33.37M | Net cash position 2023 | 12M 13.21M 18.13M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.62% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
1st Jan change | Capi. | |
---|---|---|
+3.59% | 106B | |
+7.02% | 23.47B | |
-14.75% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.41% | 16.78B | |
+5.27% | 14.41B | |
+37.37% | 12.86B | |
+328.13% | 8.78B |